The company said the results demonstrated exparel "significantly improved pain control and reduced opioid consumption" through 48 hours compared with placebo and a "standardized" pain management protocol alone.
A total of 140 patients enrolled across 16 surgical centers in the US, Belgium, and Denmark were randomized to receive an ultrasound-guided single-dose ISNB with either exparel 133 mg (n=69) or saline placebo (n=71).
"Results from this study illustrate the clinical effectiveness of an interscalene brachial plexus nerve block with exparel, which provides prolonged pain control in a single dose without the need for additional equipment," said Manish Patel, an investigator in the study.
Price: 42.52, Change: -0.99, Percent Change: -2.28
|Insider Trends: 90-Day Buying Trend Prolonged with I...|
|Prevail Therapeutics Posts Wider-Than-Estimated Q3 Loss|
|Analyst Actions: Royal Bank of Canada Resume Coverag...|
|--Analyst Actions: Oppenheimer Lifts Fiserv's Price ...|
|Analyst Actions: Northcoast Research Downgrades Wrig...|